drreddys.com (RDY) Short-Term Debt to Equity
The development of the R&D portfolio in complex biosimilars and oncology supports the growth of Dr. Reddy's Laboratories (RDY), while GURU.Markets analytics reports a short-term debt to equity ratio of 0.15. Stable demand for affordable generics makes revenue crisis-resistant, and broad asset diversification ensures a predictable inflow of free cash flow and reliable margins.
%3A%20Ratio%20of%20Short-Term%20Indebtedness%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_RDY_-_Dr.-Reddys-Laboratories_-_Ratio-of-Short-Term-Indebtedness-to-Capital "Dr. Reddy's Lab (RDY) - Short-Term Debt to Equity from 07/04/2022 to 11/01/2026 | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for drreddys.com (RDY)
Dr. Reddy's Laboratories (RDY) operates amidst stringent regulatory barriers and the logistical risks of the global pharmaceutical market. This metric determines the dependence of short-term liabilities on equity to assess resilience to credit tightening. By analyzing the history of short-term borrowed capital relative to equity on GURU.Markets, one can identify default risks or excessive conservatism. Investors utilize this indicator to balance financial security against return on assets.